当前位置: X-MOL 学术Expert Rev. Pharmacoecon. Outcomes Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cost-effectiveness of nivolumab in advanced melanoma: a drug review
Expert Review of Pharmacoeconomics & Outcomes Research ( IF 2.3 ) Pub Date : 2020-12-06 , DOI: 10.1080/14737167.2021.1845144
Pol Specenier 1
Affiliation  

ABSTRACT

Introduction: The immune checkpoint inhibitors, including nivolumab, and targeted agents have dramatically improved the outcome for patients with unresectable advanced melanoma.

Areas covered: This is a narrative review of the published evidence on nivolumab in metastatic melanoma.

Expert opinion: In ipilimumab pre-treated patients (CheckMate 037), nivolumab was associated with a higher response rate and a longer duration of response when compared to chemotherapy. In previously untreated patients, nivolumab improves survival when compared to chemotherapy (CheckMate 066) or to ipilimumab (CheckMate 067). The combination of nivolumab and ipilimumab also improves survival when compared to ipilimumab (CheckMate 067). CheckMate 067 was not designed to compare the nivolumab–ipilimumab combination to nivolumab alone. A modified regimen using a lower dose of ipilimumab in combination with standard dose nivolumab is better tolerated than nivolumab in combination with standard dose ipilimumab (CheckMate 511).

In patients with previously untreated metastatic melanoma, the anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab improve survival when compared to ipilimumab. Nivolumab is equally active in BRAF mutated and BRAF wild type melanoma. The optimal sequence of checkpoint inhibitors and BRAF/MEK inhibitors in BRAF mutated patients has not been established.



中文翻译:

尼沃单抗治疗晚期黑色素瘤的成本效益:药物评价

摘要

简介:包括nivolumab在内的免疫检查点抑制剂和靶向药物极大地改善了不可切除的晚期黑色素瘤患者的治疗效果。

涵盖范围:这是对有关转移性黑素瘤中尼古鲁单抗的已发表证据的叙述性综述。

专家意见:在ipilimumab预处理的患者(CheckMate 037)中,与化疗相比,nivolumab具有更高的缓解率和更长的缓解持续时间。与化疗(CheckMate 066)或依匹莫单抗(CheckMate 067)相比,以前未接受过治疗的患者尼古鲁单抗可提高生存率。与依匹莫单抗(CheckMate 067)相比,依诺单抗和依匹单抗的组合还提高了生存率。CheckMate 067并非旨在将nivolumab-ipilimumab组合与单独的nivolumab进行比较。与标准剂量的依匹莫单抗联合使用的尼伏鲁单抗(CheckMate 511)相比,使用较低剂量的依匹莫单抗与标准剂量尼古拉单抗联合的改良方案耐受性更好。

与ipilimumab相比,在先前未经治疗的转移性黑色素瘤患者中,抗PD-1单克隆抗体nivolumab和pembrolizumab可提高生存率。Nivolumab在BRAF突变和BRAF野生型黑色素瘤中同样活跃。尚未确定BRAF突变患者中检查点抑制剂和BRAF / MEK抑制剂的最佳序列。

更新日期:2021-01-29
down
wechat
bug